Home β€Ί Stock analysis β€Ί SUPN

Supernus Pharmaceuticals (SUPN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)

Updated Oct 16, 2026, 4:00 PM ET

What changed since yesterday

SUPN slides 4.3% to $37.88, a 52-week low on 2.1x normal volume. Closed at $37.88, -4.27% vs the prior close of $39.57. Day range $37.54–$39.49, opened at $39.19.

Last close$37.88-4.27%
Day range37.54–39.49
Open39.19
Volume1.44M
52-week range37.54–59.68
Avg volume (20d)779.14K

SUPN daily analysis β€” what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 16, 2026 β€” SUPN slides 4.3% to $37.88, a 52-week low on 2.1x normal volume
Oct 15, 2026 β€” SUPN dips 1.5% to $39.57, a 52-week low, 3 down days in a row
Oct 14, 2026 β€” SUPN slides 4.4% to $40.18, a 52-week low
Oct 13, 2026 β€” SUPN dips 1.9% to $42.01
Oct 12, 2026 β€” SUPN rises 0.3% to $42.81
Oct 9, 2026 β€” SUPN rises 1.3% to $42.67
Oct 8, 2026 β€” SUPN dips 2.1% to $42.14
Oct 7, 2026 β€” SUPN rises 0.5% to $43.05, 4 up days in a row
Oct 6, 2026 β€” SUPN ends flat (+0.2%) to $42.83, 3 up days in a row
Oct 5, 2026 β€” SUPN rises 0.9% to $42.76
Oct 2, 2026 β€” SUPN rises 0.5% to $42.38

SUPN latest news & SEC filings

Every SEC filing by or about SUPN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 15, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001356576-26-000040

Oct 6, 2026 Β· Form 425 β€” 425 filing

425 filing

Source: SEC EDGAR filing 0001104659-26-113884

Oct 6, 2026 Β· Form DEFA14A β€” Additional proxy materials

Additional proxy materials

Source: SEC EDGAR filing 0001104659-26-113882

Sep 11, 2026 Β· Form DEFM14A β€” DEFM14A filing

DEFM14A filing

Source: SEC EDGAR filing 0001104659-26-107109

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001539937-26-000012

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001836067-26-000010

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001539215-26-000012

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001804567-26-000014

Aug 14, 2026 Β· Form 4 β€” Insider trade

Insider trade report (Form 4) β€” a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001194020-26-000015

Aug 6, 2026 Β· Form SCHEDULE 13G/A β€” Update to a passive 5%+ stake (13G)

Update to a passive 5%+ stake (13G)

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0001104659-26-092198

Aug 4, 2026 Β· Form 425 β€” 425 filing

425 filing

Source: SEC EDGAR filing 0001193125-26-331036

Aug 3, 2026 Β· Form 425 β€” 425 filing

425 filing

Source: SEC EDGAR filing 0001193125-26-330875

Aug 3, 2026 Β· Form DEFA14A β€” Additional proxy materials

Additional proxy materials

Source: SEC EDGAR filing 0001104659-26-089849

Aug 3, 2026 Β· Form 425 β€” 425 filing

425 filing

Source: SEC EDGAR filing 0001104659-26-089848

Aug 3, 2026 Β· Form 8-K β€” Major event / current report

Current report β€” a filing companies must make within 4 business days of a major event

Source: SEC EDGAR filing 0001104659-26-089839

Things to know before you trade SUPN

SUPN market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 16, 202639.1939.4937.5437.881.44M
Oct 15, 202640.2141.3139.3639.571.01M
Oct 14, 202641.9343.2639.9740.18906.70K
Oct 13, 202642.9443.2941.7142.011.20M
Oct 12, 202642.6743.2041.9042.81914.60K
Oct 9, 202642.1843.1442.1542.67643.80K
Oct 8, 202642.4143.4141.1442.14684.20K
Oct 7, 202642.2443.3842.2443.05571.00K
Oct 6, 202642.8643.1241.4042.83748.30K
Oct 5, 202642.3843.2042.3842.761.29M
Oct 2, 202642.4743.1541.8842.38739.80K
Oct 1, 202643.2143.6942.1542.18424.60K
Sep 30, 202644.0344.1843.0343.04685.60K
Sep 29, 202644.3944.9343.2043.97551.60K
Sep 28, 202642.5944.6142.3844.60728.10K
Sep 25, 202643.2143.6942.6542.66607.60K
Sep 24, 202643.2244.0042.7743.29589.00K
Sep 23, 202643.6644.4643.1443.39544.50K
Sep 22, 202643.0444.2542.8243.75667.60K
Sep 21, 202642.0042.9741.6842.78635.70K

About Supernus Pharmaceuticals

Supernus Pharmaceuticals (SUPN) is listed on the Nasdaq and classified by the SEC under β€œPharmaceutical Preparations”. Its business address is in ROCKVILLE, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1356576.

SUPN board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Carrolee BarlowDirectorFeb 25, 2026
Georges GemayelDirectorMar 9, 2026
Frederick M. HudsonDirectorMar 16, 2026
Jack A. KhattarPresident, CEOAug 14, 2026
Charles W Iii NewhallDirectorFeb 25, 2026
Bethany SensenigDirectorFeb 23, 2026

Executive officers

NameTitleLatest filing
Padmanabh P. BhattSr. VP of IP, CSOAug 14, 2026
Timothy C DecSenior Vice-President & CFOAug 14, 2026
William Todd HorichSVP, Commercial OperationsMar 10, 2026
Jack A. KhattarPresident, CEOAug 14, 2026
Frank MottolaSVP, Chief Tech. Ops. OfficerAug 14, 2026
Jonathan RubinSVP, Chief Medical OfficerAug 14, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
Mar 18, 2026Padmanabh P. BhattSale412$50.48
Mar 18, 2026Padmanabh P. BhattSale6,838$49.55
Mar 18, 2026Padmanabh P. BhattSale412$50.48
Mar 18, 2026Padmanabh P. BhattSale6,838$49.55
Mar 18, 2026Padmanabh P. BhattSale412$50.48
Mar 18, 2026Padmanabh P. BhattSale6,838$49.55
Mar 18, 2026Padmanabh P. BhattSale412$50.48
Mar 18, 2026Padmanabh P. BhattSale6,838$49.55
Mar 17, 2026Padmanabh P. BhattSale27,710$49.95
Mar 17, 2026Padmanabh P. BhattSale22,290$50.73
Mar 17, 2026Padmanabh P. BhattSale27,710$49.95
Mar 17, 2026Padmanabh P. BhattSale22,290$50.73
Mar 17, 2026Padmanabh P. BhattSale27,710$49.95
Mar 17, 2026Padmanabh P. BhattSale22,290$50.73
Mar 17, 2026Padmanabh P. BhattSale27,710$49.95

SUPN financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025$718.95M$-38.55M-0.68$47.33M
Dec 31, 2024$661.82M$73.86M1.32$171.95M
Dec 31, 2023$607.52M$1.32M0.02$111.08M
Dec 31, 2022$667.24M$60.71M1.04$116.83M
Dec 31, 2021$579.77M$53.42M0.98$127.13M

Latest balance sheet: total assets $1.43B, total liabilities $396.88M, cash $179.95M (as of Jun 30, 2026).

SUPN earnings / results-day log

DateFilingClose that day
Aug 3, 20268-K Item 2.02 (results)$46.00
Jul 22, 20268-K Item 2.02 (results)$46.94
May 5, 20268-K Item 2.02 (results)$49.19
Apr 22, 20268-K Item 2.02 (results)$50.29
Feb 24, 20268-K Item 2.02 (results)$53.30
Feb 12, 20268-K Item 2.02 (results)$49.85
Nov 4, 20258-K Item 2.02 (results)$57.00
Oct 21, 20258-K Item 2.02 (results)$50.67
Aug 5, 20258-K Item 2.02 (results)$37.53
Jul 22, 20258-K Item 2.02 (results)$32.67
May 6, 20258-K Item 2.02 (results)$32.43
Apr 23, 20258-K Item 2.02 (results)$30.84

Related stocks Β· Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)

More on SUPN

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.